Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 14/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144615 | 0.87 | P2RY14 (0.34) | P2RY6P2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL16144276 | 0.86 | POLG (0.40) | P2RY6P2RY2P2RY4P2RY12 | |
| SCHEMBL16144258 | 0.85 | P2RY14 (0.37) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL16148814 | 0.85 | P2RY14 (0.37) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL16144259 | 0.85 | P2RY14 (0.36) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL16107756 | 0.84 | P2RY14 (0.34) | P2RY6P2RY14 | |
| SCHEMBL16107755 | 0.84 | P2RY14 (0.34) | P2RY6P2RY14 | |
| SCHEMBL16144343 | 0.81 | P2RY6 (0.58) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL25400121 | 0.80 | P2RY14 (0.37) | P2RY6P2RY14P2RY2P2RY12 | |
| SCHEMBL16144255 | 0.79 | P2RY6 (0.60) | P2RY6POLA1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2014165542-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | P2RY6 748/4885P2RY14 794/4885POLA1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.